HER3 Mutations Affect Tumor Response to HER2-Targeted Therapies.
Sign Up to like & getrecommendations! Published in 2021 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2021-093
Abstract: HER3 missense mutations can inhibit response of tumor cells to HER2-targeted therapies. read more here.
Keywords: response; her2 targeted; her3 mutations; targeted therapies ... See more keywords
Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0267027
Abstract: ErbB3 (HER3), a member of the HER family, is overexpressed in various cancers and plays an important role in cell proliferation and survival. Certain HER3 mutations have also been identified as oncogenic drivers, making them… read more here.
Keywords: her3 mutations; her3; her2 overexpression; activity ... See more keywords